Just weeks after Sanofi-Aventis and Regeneron reported poor results with their cancer drug aflibercept in a late-stage study of non-small cell lung cancer, researchers gave a thumbs-up to their top-line results produced in a Phase III study for colon cancer. The two developers said that the drug--to be sold as Zaltrap--will be filed for marketing approval later this year.
"We are pleased with the results of the Zaltrap Phase III study in this group of patients," said Debasish Roychowdhury, senior vice president and head of Sanofi's global oncology division. "We are committed to bringing Zaltrap to patients with advanced colorectal cancer and maximizing the therapeutic potential of this unique and exciting medicine."
Zaltrap is expected to grab about $200 million per year of the colon cancer market it addresses. In addition to the stopped lung cancer trial, aflibercept has been discontinued in an ovarian cancer trial but still is being used in an ongoing trial for metastatic prostate cancer. See Fierce Biotech.